Investors

Investors

An emerging leader in the immunotherapy space, we are advancing a pre-clinical pipeline of therapeutic candidates intended to elicit broad and durable anti-tumor and anti-viral responses and cure disease.

Stock Quote

Current value on NASDAQ*

*Stock Price may not reflect real time results

SEC Filings

U.S. Securities and Exchange Commission filings
View SEC Filings

Investor Contact

Will  O’Conner
Stern Investor Relations
will.oconnor@sternir.com

Indaptus Management

View Management Team

Indaptus Board of Directors

View Board of Directors

Documents

November 15, 2021

Investor Presentation